Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel

By The Gray Sheet / “The Gray Sheet” Aug. 24, 2009, Vol. 35, No. 034
Advisory Panels / Word Count: 867 / Article # 01350340005

Executive Summary

Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 867-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
Companies
Dartmouth-Hitchcock Medical Center

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Gray Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel